Lexicon: Beaten Down Stock, High Risk-Reward Situation Ahead (NASDAQ:LXRX)
seekingalpha.com
finance
2022-05-31 15:00:00

Diego Thomazini/iStock via Getty Images I covered Lexicon (NASDAQ:LXRX) in February last year. Sotagliflozin is its lead asset targeting the SGLT1/2 glucose transporters. It is the first dual SGLT1/SGLT2 inhibitor targeting diabetes. Jardiance from Eli Lilly (LLY) and Boehringer Ingelheim, and Farxiga from AstraZeneca (AZN), two SGLT2-only blockers, are blockbuster drugs, while Sotagliflozin has not found favor with the FDA despite good data generally. The molecule has one NDA pending resubmission in heart failure in certain patients with type 2 diabetes or T2DM, and another with a CRL in Type 1 diabetes with "ongoing regulatory engagement.
